Table 3

Expression levels and fluorescence intensity of MHC and co-stimulatory molecules on the surface of 5-FU-treated cellsa, b.

Cell type

Percentage of molecule expression, %

Average fluorescence intensity


MHC I

MHC II

CD80

CD86

MHC I

MHC II

CD80

CD86


CT-26

Treated

92.7 ± 2.76

10.0 ± 1.56c

92.4 ± 7.85

9.2 ± 1.84c

13.6 ± 0.21c

12.5 ± 0.42d

4.3 ± 0.14c

3.5 ± 0.49c

Untreated

99.1 ± 1.27

1.5 ± 0.14

83.4 ± 6.58

3.1 ± 2.47

38.9 ± 2.34

5.0 ± 0.49

2.7 ± 0.35

1.8 ± 0.64

TC-1

Treated

92.4 ± 2.69

1.6 ± 0.49

95.9 ± 4.03

5.3 ± 0.10c

3.0 ± 0.35c

3.6 ± 0.92c

10.7 ± 0.99c

2.9 ± 1.06

Untreated

97.5 ± 2.47

0.4 ± 0.07

95.0 ± 1.27

1.6 ± 0.49

8.2 ± 0.78

2.3 ± 0.64

5.6 ± 0.14

1.8 ± 0.71

4T-1

Treated

69.7 ± 6.65

10.5 ± 1.13d

11.3 ± 1.27c

7.8 ± 1.27c

2.6 ± 0.49c

5.4 ± 0.49c

4.4 ± 0.85

3.5 ± 1.06

Untreated

84.4 ± 0.64

2.4 ± 1.20

2.7 ± 0.71

1.8 ± 0.07

3.8 ± 0.07

3.2 ± 0.64

2.7 ± 1.13

2.4 ± 0.92


Abbreviations: MHC, major histocompatibility complex.

aExperiments were repeated twice with similar results.

bData are expressed as mean ± SD of the two independent experiments.

c, dThe t-test was carried out to determine the difference between the two groups in three experiments: cP < 0.05, dP < 0.01, t-test).

Sun et al. BMC Medicine 2012 10:172   doi:10.1186/1741-7015-10-172

Open Data